|
| (Ref.) |
|
Antimitogenic (particularly towards PA-SMCs) | |
PDGF inhibitors | [4] |
Endothelin receptor blockers | [16–19, 29] |
Prostacyclin (analogue) | [5–10, 15, 19] |
Serotonin transporter inhibitors | [21] |
Serotonin receptor blockers | [23, 24] |
Serotonic re-uptake inhibitor | [22] |
PDE 4/5 and 3/4 inhibitors | [9, 10, 25–29] |
Caveolin-1 peptide | [30] |
Estradiol (derivatives) | [31–34] |
Amlodipine | [38] |
Rapamycin | [42] |
Cell therapy using differentiated cells transduced with eNOS gene | [60, 62, 63, 68] |
Prostacyclin synthase gene | [55, 56] |
NF-κB inhibitor | [44] |
Serine-elastase inhibitors | [3] |
Proendothelial function, vasodilatation, and proangiogenesis | |
Rho-kinase inhibitors | [11–15] |
Statins | [35–37] |
Nicorandil | [39] |
Granulocyte-colony stimulating factor | [43] |
L-arginine | [50] |
Prostacyclin (analogue) | [5–10, 15, 19] |
Endothelin receptor blockers | [16–19, 29] |
PDE 4/5 and 3/4 inhibitors | [9, 10, 25–29] |
Adrenomedullin | [41] |
Prostacyclin synthase gene | [55, 56] |
Angiopoietin-1 gene | [57] |
Cell therapy using EPCs and MSCs | [59, 63–65, 68–71] |
Cell therapy using differentiated cells transduced with eNOS gene | [60, 62, 63, 68] |
Cell therapy using differentiated cells transduced with VEGF gene | [61, 62] |
Anti-inflammatory and antioxidative | |
Serotonin receptor blockers | [23, 24] |
Amlodipine | [38] |
Nicorandil | [39] |
Statins | [35–37] |
C-type natriuretic factor | [40] |
Interleukin-1 receptor antagonist | [45] |
Antibodies to monocyte chemotactic and activating factor/MCP1 | [46] |
Inhibitor of p38 mitogen-activated protein kinase | [47] |
Inhibitor of lipoxygenase pathways | [51] |
Antimonocyte chemoattractant protein-1 gene | [54] |
Interleukin-10 gene | [58] |
Extracellular superoxide dismutase gene | [53] |
|